TL3: High placebo response, what is your story?
*Anastasia Ivanova, UNC at Chapel Hill Keywords: placebo run-in, placebo lead-in, active run-in, SPCD In a survey (Laughren, European Psychiatry, 2001) of placebo-control trials in depression and schizophrenia considered by FDA over 12 year period, 1987 through 1999, it was noted that many of the studies in which investigational drug could not be distinguished from placebo also included an active standard drug that could not be distinguish from placebo. Various designs have been proposed for trials with high placebo response including (1) placebo or active lead-in designs and (2) the sequential parallel comparison design (SPCD) where the trial is conducted in two stages with each stage being sufficiently long to observe the outcome. What is the best way to lower the impact of high placebo response on the success of a clinical trial?
|
Key Dates
-
November 1 - December 17, 2013
Online proposal submission for a session, short course and Town Hall Open -
January 6 - March 11, 2014
Online proposal submission for Roundtables Open -
April 30 - May 28, 2014
Abstract Submission Open -
June 4, 2014
Online Registration Opens -
August 8 - August 22, 2014
Invited Abstract Editing -
August 11, 2014
Short Course materials due from Instructors -
September 1, 2014
Housing Deadline -
September 15, 2014
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 22 - September 24, 2014
Marriott Wardman Park, Washington, DC